Behavioral effects of N-desmethylclozapine on locomotor activity and sensorimotor gating function in mice-Possible involvement of muscarinic receptors

Brain Research

Volumn 1418, Issue , 2011, Pages 111-119

  Maehara, Shunsuke ^a,b   Hikichi, Hirohiko ^a   Ohta, Hisashi ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Locomotor activity; Muscarinic receptors; N desmethylclozapine; Prepulse inhibition; Xanomeline

Indexed keywords

CLOZAPINE; NORCLOZAPINE; OXOTREMORINE; SCOPOLAMINE; XANOMELINE;

ARTICLE; CONTROLLED STUDY; DBA 2 MOUSE; DRUG ACTIVATION; DRUG EFFECT; EXPLORATORY BEHAVIOR; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION;

ACOUSTIC STIMULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MICE; MOTOR ACTIVITY; MUSCARINIC AGONISTS; NEURAL INHIBITION; OXOTREMORINE; PSYCHOPHYSICS; PYRIDINES; RECEPTORS, MUSCARINIC; SCOPOLAMINE HYDROBROMIDE; SENSORY GATING; THIADIAZOLES;

ANIMALIA; MUS;

EID: 80053386273     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2011.08.056     Document Type: Article

References (29)

1. S. Ahlenius, and V. Hillegaart Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and post- synaptic inhibition of dopaminergic neurotransmission Pharmacol. Biochem. Behav. 24 1986 1409 1415 (Pubitemid 16067429)
2. M. Aravagiri, and S.R. Marder Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients J. Pharm. Biomed. Anal. 26 2001 301 311 (Pubitemid 32709945)
3. D.E. Baldessarini, and F.R. Frankenburg Clozapine a novel antipsychotic agent N. Engl. J. Med. 324 1991 746 754
4. R.J. Baldessarini, F. Centorrino, J.G. Flood, S.A. Volpicelli, D. Huston-Lyons, and B.M. Cohen Tissue concentrations of clozapine and its metabolites in the rat Neuropsychopharmacology 9 1993 117 124 (Pubitemid 23275837)
5. N.C. Bodick, W.W. Offen, A.I. Levey, N.R. Cutler, S.G. Gauthier, A. Satlin, H.E. Shannon, G.D. Tollefson, K. Rasmussen, F.P. Bymaster, D.J. Hurley, W.Z. Potter, and S.M. Paul Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease Arch. Neurol. 54 1997 465 473 (Pubitemid 27172867)
6. 1 muscarinic agonist xanomeline (LY246708/NNC11-0232) J. Pharmacol. Exp. Ther. 269 1994 282 289
7. F.P. Bymaster, C.A. Whitesitt, H.E. Shannon, N. DeLapp, J.S. Ward, D.O. Calligaro, L.A. Shipley, J.L. Buelke-Sam, N.C. Bodick, L. Farde, M.J. Sheardown, P.H. Olesen, K.T. Hansen, P.D. Suzdak, M.D. Swedberg, P. Sauerberg, and C.H. Mitch Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease Drug. Dev. Res. 40 1997 158 170 (Pubitemid 27281623)
8. 1 muscarinic acetylcholine receptor-deficient mice Proc. Natl. Acad. Sci. 98 2001 15312 15317 (Pubitemid 34014011)
9. J. Gerlach, and L. Peacock Motor and mental side-effects of clozapine J. Clin. Psychiatry 55 1994 107 109
10. C. Guitton, J.M. Kinowski, R. Gomeni, and F. Bressolle A kinetic model for simultaneous fit of clozapine and norclozapine concentrations in chronic schizophrenic patients during long-term treatment Clin. Drug. Invest. 16 1998 35 43 (Pubitemid 28362473)
11. C.K. Jones, E.L. Eberle, D.B. Shaw, D.L. McKinzie, and H.E. Shannon Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats J. Pharmacol. Exp. Ther. 312 2005 1055 1063 (Pubitemid 40293764)
12. G.G. Kinney, C. Sur, M. Burno, P.J. Mallorga, J.B. Williams, D.J. Figueroa, M. Wittmann, W. Lemaire, and P.J. Conn The glycine transporter type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl] sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior J. Neurosci. 23 2003 7586 7591 (Pubitemid 37034075)
13. 1 muscarinic receptors Neuropsychopharmacololgy 30 2005 1986 1995 (Pubitemid 43093499)
14. Z. Li, S. Shikha, A.S. Roseman, J. Dai, and H.Y. Meltzer Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine Eur. J. Pharmacol. 596 2008 89 97
15. S. Maehara, H. Hikichi, A. Satow, S. Okuda, and H. Ohta Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia Pharmacol. Biochem. Behav. 91 2008 140 149
16. 1 muscarinic receptors Eur. J. Pharmacol. 667 2011 242 249
17. J. McCaughran, E. Mahjubi, E. Decena, and R. Hitzemann Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition Psychopharmacology 134 1997 131 139 (Pubitemid 27522568)
18. 1 muscarinic acetylcholine receptor J. Neurosci. 21 2001 5239 5250 (Pubitemid 32622949)
19. B. Olivier, C. Leahy, T. Mullen, R. Paylor, V.E. Groppi, Z. Sarnyai, and D. Brunner The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics? Psychopharmacology 156 2001 284 290 (Pubitemid 32702219)
20. A. Safferman, J. Lieberman, and J. Kane Update on clinical efficacy and side-effects of clozapine Schizophr. Bull. 17 1991 247 262
21. 1 receptors J. Pharmacol. Exp. Ther. 269 1994 271 281 (Pubitemid 24143264)
22. A. Shekhar, W.Z. Potter, J. Lightfoot, J. Lienemann, S. Dubé, C. Mallinckrodt, F.P. Bymaster, D.L. McKinzie, and C.C. Felder Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia Am. J. Psychiatry 165 2008 1033 1039
23. K.J. Stanhope, N.R. Mirza, M.J. Bickerdike, J.L. Bright, N.R. Harrington, M.B. Hesselink, G.A. Kennett, S. Lightowler, M.J. Sheardown, R. Syed, R.L. Upton, G. Wadsworth, S.M. Weiss, and A. Wyatt The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat J. Pharmacol. Exp. Ther. 299 2001 782 792
24. C. Sur, P.J. Mallorga, M. Wittmann, M.A. Jacobson, D. Pascarella, J.B. Williams, P.E. Brandish, D.J. Pettibone, E.M. Scolnick, and P.J. Conn N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity Proc. Natl. Acad. Sci. 100 2003 13674 13679 (Pubitemid 37444798)
25. 4 muscarinic receptors in mice Psychopharmacology 208 2010 401 416
26. J. Volavka, P. Czobor, B. Sheitman, J.P. Lindenmayer, L. Citrome, J.P. McEvoy, T.B. Cooper, M. Chakos, and J.A. Lieberman Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder Am. J. Psychiatry. 159 2002 255 262 (Pubitemid 34126903)
27. H. Weigmann, S. Härtter, V. Fischer, N. Dahmen, and C. Hiemke Distribution of clozapine and desmethylclozapine between blood and brain in rats Eur. Neuropsychopharmacol. 9 1999 253 256 (Pubitemid 29114932)
28. D.M. Weiner, H.Y. Meltzer, I. Veinbergs, E.M. Donohue, T.A. Spalding, T.T. Smith, N. Mohell, S.C. Harvey, J. Lameh, N. Nash, K.E. Vanover, R. Olsson, K. Jayathilake, M. Lee, A.I. Levey, U. Hacksell, E.S. Burstein, R.E. Davis, and M.R. Brann The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine Psychopharmacology 177 2004 207 216 (Pubitemid 40109932)
29. 1 receptor knockout mice Eur. J. Pharmacol. 603 2009 147 149